For research use only. Not for therapeutic Use.
TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells[1].
| Catalog Number | I043731 |
| CAS Number | 2253744-56-6 |
| Synonyms | 7-[[5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl]methyl]-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione |
| Molecular Formula | C20H20Cl2N8O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H20Cl2N8O3/c1-27-16-15(18(31)28(2)20(27)32)30(19(24-16)29-7-5-23-6-8-29)10-14-25-26-17(33-14)11-3-4-12(21)13(22)9-11/h3-4,9,23H,5-8,10H2,1-2H3 |
| InChIKey | QXCXMVYVUHVFLP-UHFFFAOYSA-N |
| SMILES | CN1C2=C(C(=O)N(C1=O)C)N(C(=N2)N3CCNCC3)CC4=NN=C(O4)C5=CC(=C(C=C5)Cl)Cl |
| Reference | [1]. Page BDG, et al. Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells [published correction appears in Nat Commun. 2019 Nov 1;10(1):5050]. Nat Commun. 2018;9(1):250. |
